Target Name: GOLM1
NCBI ID: G51280
Review Report on GOLM1 Target / Biomarker Content of Review Report on GOLM1 Target / Biomarker
GOLM1
Other Name(s): GOLM1_HUMAN | golgi membrane protein GP73 | HEL46 | bA379P1.3 | GOLM1 variant 1 | GP73 | PSEC0257 | golgi phosphoprotein 2 | C9orf155 | Golgi phosphoprotein 2 | golgi membrane protein 1 | Golgi membrane protein GP73 | Golgi membrane protein 1, transcript variant 1 | GOLPH2 | golgi protein, 73-kD | Golgi membrane protein 1 | epididymis luminal protein 46

GOLM1: A Potential Drug Target and Biomarker for Various Diseases

GOLM1 (GOLM1_HUMAN), a gene located on chromosome 6, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

GOLM1 is a gene that encodes a protein known as GOLM1, which is involved in the development and maintenance of tissues, including brain and spinal cord tissues. The GOLM1 protein has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

One of the most significant findings related to GOLM1 is its involvement in the development of cancer. Several studies have shown that high levels of GOLM1 are associated with an increased risk of cancer development. For example, a study published in the journal \"Cancer Research\" found that individuals with certain genetic mutations, which are often associated with cancer, had lower levels of GOLM1 compared to individuals without these mutations.

Another study published in the journal \"Molecular Therapy\" found that inhibiting the GOLM1 gene was effective in treating cancer cells. The researchers found that when they inhibited the GOLM1 gene, they were able to significantly reduce the growth of cancer cells.

In addition to its association with cancer, GOLM1 has also been linked to the development of neurodegenerative disorders and autoimmune diseases. For example, a study published in the journal \"Neurodegenerative Disorders\" found that individuals with a specific genetic mutation, which is associated with neurodegenerative disorders, had lower levels of GOLM1 compared to individuals without this mutation.

The implications of these findings are significant. If GOLM1 is indeed a drug target and biomarker for various diseases, then targeting it may provide new insights into the development and treatment of these conditions. For example, if GOLM1 is associated with cancer, then inhibiting the GOLM1 gene may be a promising new approach to cancer treatment. Similarly, if GOLM1 is associated with neurodegenerative disorders and autoimmune diseases, then targeting it may provide new insights into the development and treatment of these conditions.

GOLM1 is also of interest as a potential biomarker for disease diagnosis and monitoring. The GOLM1 protein has been shown to be expressed in a variety of tissues and cells, including brain, spinal cord, and immune cells. This suggests that it may be a useful biomarker for the diagnosis and monitoring of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

In conclusion, GOLM1 is a gene that has significant implications for our understanding of the development and treatment of various diseases. Its involvement in the development and progression of cancer, neurodegenerative disorders, and autoimmune diseases makes it a promising target for drug development and disease treatment. Further research is needed to fully understand the role of GOLM1 in these conditions and to develop effective treatments.

Protein Name: Golgi Membrane Protein 1

Functions: Unknown. Cellular response protein to viral infection

The "GOLM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GOLM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GOLM2 | GOLPH3 | GOLPH3L | GOLT1A | GOLT1B | GON4L | GON7 | GOPC | GORAB | GORASP1 | GORASP2 | GOSR1 | GOSR2 | GOT1 | GOT1-DT | GOT1L1 | GOT2 | GOT2P1 | GP1BA | GP1BB | GP2 | GP5 | GP6 | GP9 | GPA33 | GPAA1 | GPALPP1 | GPAM | GPANK1 | GPAT2 | GPAT3 | GPAT4 | GPATCH1 | GPATCH11 | GPATCH2 | GPATCH2L | GPATCH3 | GPATCH4 | GPATCH8 | GPBAR1 | GPBP1 | GPBP1L1 | GPC1 | GPC1-AS1 | GPC2 | GPC3 | GPC4 | GPC5 | GPC5-AS1 | GPC5-AS2 | GPC6 | GPC6-AS1 | GPC6-AS2 | GPCPD1 | GPD1 | GPD1L | GPD2 | GPER1 | GPHA2 | GPHB5 | GPHN | GPI | GPI transamidase complex | GPI-GlcNAc transferase complex | GPIHBP1 | GPKOW | GPLD1 | GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1